multiple myeloma
Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment
July 30, 2025Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma
Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …
CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma
May 23, 2025Market & Product Development, Medical Communications, Research and Development Blenrep, Committee for Medicinal Products for Human USE, European Medicines Agency, Oncology, multiple myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …
Multiple myeloma treatment approved in Japan
May 21, 2025Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …
MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients
January 30, 2025Research and Development MHRA, Oncology, approvals, multiple myeloma, rare diseases
The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in combination to treat multiple myeloma …
AbbVie initiates phase 3 multiple myeloma trial
June 6, 2024Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …
Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
June 5, 2024Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …
Sanofi’s Sarclisa accepted for FDA priority review
May 29, 2024Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
Heidelberg Pharma gains FDA ODD for ATAC candidate
March 27, 2024Research and Development FDA, Oncology, heidelberg pharma, multiple myeloma
Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) …
GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma
March 7, 2024Research and Development Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab …
Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment
February 5, 2024Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …
FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment
January 30, 2024Research and Development FDA, Gracell Biotechnologies, Oncology, clinical trial, multiple myeloma
Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, …
EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma
December 12, 2023Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma
Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
November 27, 2023Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …
FDA grants ODD to NXC-201 as multiple myeloma treatment
August 24, 2023Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma
Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …
FDA approves Talvey for the treatment of heavily pretreated multiple myeloma
August 11, 2023Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma
The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …
Latest content
FibroFind appoints Lee Borthwick as CEO
